Real-World Evidence of Duration of Effect of Adhansia XR (Extended-Release) for Treatment of Attention-Deficit/Hyperactivity Disorder (ADHD)

Attention-Deficit/Hyperactivity Disorder Clinical Trial

— RE-DAX  

Official title:

Real-world Evidence of Duration of Adhansia XR for Treatment of ADHD (RE-DAX): An Open-label Pragmatic Study to Assess the Real-world Effectiveness of Adhansia XR in Treatment of Adult and Adolescent Patients With ADHD in the United States

Clinical Trial Details — Status: Terminated

Administrative data

• NCT number: NCT04507204
• Other study ID #: ADA4003
• Status: Terminated
• Phase: Phase 4
• Start date: July 30, 2020
• Est. completion date: January 31, 2022

Study information

• Verified date: July 2023
• Source: Purdue Pharma LP
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of this study is to investigate the treatment effectiveness of Adhansia XR at month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (Concerta) over time.

Description:

This phase IV study is a prospective, open-label, randomized, pragmatic study to investigate the treatment effectiveness of Adhansia XR at Month-2 after initiation, and the effectiveness of Adhansia XR overall and when compared with the active comparator group (OROS MPH or Concerta) over time. Additional outcome assessments for both treatment arms include Health-Related Quality of Life (HRQoL) during the 6-month follow-up period. The burden of illness (BOI) will be investigated by collecting additional measures such as healthcare resource utilization (HCRU), broader treatment patterns, and comorbidities.

Recruitment information / eligibility

• Status: Terminated
• Enrollment: 267
• Est. completion date: January 31, 2022
• Est. primary completion date: December 22, 2021
• Accepts healthy volunteers: No
• Gender: All
• Age group: 12 Years and older

Eligibility

Inclusion Criteria:

• Patients with a physician-confirmed diagnosis of ADHD per Diagnostic and Statistical Manual of Mental Disorders (DSM-5) criteria and the health care practitioner (HCP) has made the decision to prescribe an extended-release methylphenidate (ER MPH) product to the patient for potential improvement of symptoms throughout and later in the day, independent of this study.
• Patient must be 12 years of age or older.
• Patient must be eligible to receive Adhansia XR or osmotic- release oral delivery system methylphenidate ([OROS MPH] or Concerta) according to the US product labels; a patient must be eligible and willing to receive either drug, as randomization will assign them to a specific treatment group. Patient may be treatment-experienced or naïve to pharmacological therapy for ADHD, so long as all inclusion and no exclusion criteria are met.
• Patient must be willing to take only the assigned study medication per HCP instructions based on FDA label guidance for treatment of their ADHD for the first 2 months of the study (i.e. full titration period). Patients should not be on any other medication, or starting any new non-medication treatment, proven to have effect on ADHD in the first two months of the study.

Exclusion Criteria:

• Concurrent participation in an investigational study in which patient assessment and/or treatment may be dictated by a protocol.
• Patients with a true allergy to methylphenidate (MPH), amphetamine (AMP), or sympathomimetic amines, history of serious adverse reactions to MPH or AMP or be known to be non-responsive to MPH or AMP treatment.
• Patient is currently stable on their ADHD treatment regimen.
• Female patients of child bearing potential who are pregnant, planning on becoming pregnant or breastfeeding.
• Patient with any known conditions that are contraindicated for either Adhansia XR or OROS MPH (or Concerta) use, as documented in the US Full Prescribing Information, including patients with any known serious structural cardiac abnormalities, cardiomyopathy, serious heart arrhythmias, or coronary artery disease.
• Patients with a known sensitivity to the food dye tartrazine (Federal Food, Drug, and Cosmetic Yellow No. 5).
• Suicidal Ideation
• The Columbia-Suicide Severity Rating Scale (C-SSRS) will be administered at screening and at Month-2, Month-4, and Month-6, but also depends on the judgment of the HCP.
• Inability or unwillingness of the patient (or parent/guardian if patient is a minor) to complete the study-required electronic questionnaires and provide required information through electronic means.

Related Conditions & MeSH terms

• Attention Deficit Disorder with Hyperactivity
• Attention-Deficit/Hyperactivity Disorder
• Hyperkinesis

Intervention

Drug:
• Adhansia XR
Methylphenidate extended-release capsules taken once daily (25 mg, 35 mg, 45 mg, 55 mg, 70 mg, and 85 mg)
• Concerta
An osmotic-controlled oral release delivery system (OROS) of methylphenidate HCl (MPH) extended-release tablets taken once daily (18 mg, 27 mg, 36 mg, and 54 mg)

Locations

Country	Name	City	State
United States	Clinical Integrative Research Center of Atlanta	Atlanta	Georgia
United States	Rainbow Research	Barnwell	South Carolina
United States	Southern California Research LLC	Beverly Hills	California
United States	Neurobehavioral Medicine Group	Bloomfield Hills	Michigan
United States	Center for Emotional Fitness	Cherry Hill	New Jersey
United States	Mid-Ohio Behavioral Health	Columbus	Ohio
United States	CT Clinical Research	Cromwell	Connecticut
United States	FutureSearch Trials of Dallas, LP	Dallas	Texas
United States	InSite Clinical Research, LLC	DeSoto	Texas
United States	Harmonex, Inc.	Dothan	Alabama
United States	Duke University Medical Center	Durham	North Carolina
United States	Revive Research Institute	Elgin	Illinois
United States	Eastside Therapeutic Resource Inc dba Core Clinical Research	Everett	Washington
United States	Gulfcoast Clinical Research Center	Fort Myers	Florida
United States	Eastern Research. Inc.	Hialeah	Florida
United States	Reliable Clinical Research, LLC	Hialeah	Florida
United States	Red Oak Psychiatry Associates, PA	Houston	Texas
United States	Clinical Research of Southern Nevada, LLC	Las Vegas	Nevada
United States	Wellness Research Center Inc.	Miami	Florida
United States	Bioscience Research, LLC	Mount Kisco	New York
United States	AMR-Baber Research Inc.	Naperville	Illinois
United States	BTC of New Bedford, LLC	New Bedford	Massachusetts
United States	Icahn School of Medicine at Mount Sinai	New York	New York
United States	Psychiatric Care and Research Center	O'Fallon	Missouri
United States	AdventHealth Medical Group Pediatrics at Orange City	Orange City	Florida
United States	Clinical Research Partners, LLC	Petersburg	Virginia
United States	Rochester Center for Behavioral Medicine	Rochester Hills	Michigan
United States	St. Charles Psychiatric Associates - Midwest Research Group	Saint Charles	Missouri
United States	Dixie Pediatrics	Saint George	Utah
United States	Road Runner Research, Ltd.	San Antonio	Texas
United States	SFM Clinical Trials	Scotland	Pennsylvania
United States	MultiCare Health System - Rockwood Clinic	Spokane	Washington
United States	Richmond Behavioral Associates	Staten Island	New York
United States	Pediatric Epilepsy & Neurology Specialists	Tampa	Florida
United States	Family Psychiatry of the Woodlands	The Woodlands	Texas

Sponsors (1)

Lead Sponsor	Collaborator
Purdue Pharma LP

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in ADHD-Rating Scale 5 (ADHD-RS-5) Total Score From Baseline to Month 2 Among Patients Treated With Adhansia XR	The ADHD-RS-5 assesses the frequency and severity of each of the 18 ADHD symptoms among adults based on DSM-5 criteria. Each of the 18 DSM-5 symptoms are rated on a 4 point scale from 0 (never or rarely) to 3 (very often), yielding a total score of 0 to 54. A higher score corresponds to worse ADHD severity.	Baseline to Month-2
Secondary	Difference in Time Sensitive ADHD Symptom Scale (TASS) Between Treatment Groups to Establish Non-inferiority	TASS was completed at the end of waking hours (14 - 16 hours post-dosing) at Month-2 after baseline visit. TASS was developed to capture the change in ADHD symptoms over the course of a day and consists of 18 items that directly correspond to the 18 ADHD symptom domains listed in the DSM-5. Each item is scored on a 4-point scale as follows: 0 (none), 1 (mild), 2 (moderate), and 3 (severe); the maximum total score is 54. A higher total score corresponds to worse ADHD severity.	Month-2
Secondary	Assessment of Clinical Global Impression-Severity (CGI-S)	The CGI-S rates symptoms from 1 (not ill) to 7 (extremely ill). A higher score corresponds to higher ADHD severity.	Baseline, Month-2, Month-4, and Month-6
Secondary	Assessment of Clinical Global Impression-Improvement (CGI-I)	The CGI-I measures global improvement prior to and after initiating the study medication. The CGI-I scale is 1 question, and rates improvement compared with the baseline visit using a 7-point scale. The range of responses are from 1 (very much improved) through 7 (very much worse). A higher score corresponds to higher ADHD severity.	Month-2, Month-4, and Month-6
Secondary	Assessment of Treatment Satisfaction	The Treatment Satisfaction Questionnaire for Medications (TSQM) measures a patient's level of satisfaction or dissatisfaction with the study medication. It assesses perceptions of effectiveness, side effects and convenience of the medication and consists of 14 items that evaluate these three domains and one global scale item (ie, global satisfaction). Scores for each domain are computed by adding the TSQM items in each domain and then transforming the composite score into a value ranging from 0 to 100.; A lower score indicates a lower satisfaction with treatment.	Month-1, Month-2, and Month-6
Secondary	Healthcare Resource Utilization (HCRU)	A comparison of the frequency of health care encounters between the 2 treatment groups. Healthcare resource utilization were evaluated monthly by comparing the frequency of clinic visits (outpatient), inpatient/hospitalizations (and length of stay), and emergency department visits between the 2 treatment groups.	Baseline (past 6 months) Months -2, -4, and -6
Secondary	Adult ADHD Quality of Life Scale - Revised (AAQoL-R)	Used to assess health-related quality of life for adult patients. The AAQoL yields a total score based on 29 items. The raw scores are transformed to a 0 to 100 scale with higher scores indicating a better quality of life.	Baseline, Months -1, -2, -3, -4, -5 and -6
Secondary	Work Productivity and Activity Impairment (WPAI) Questionnaire	The WPAI questionnaire is designed to measure the effect of general health and symptom severity on work productivity and regular activities during the past 7 days. It consists of 4 domains [absenteeism (missing work), presenteeism (impaired productivity at work), overall work performance (combined absenteeism and presenteeism), and non-work activities (activity impairment)]. WPAI outcomes are expressed as impairment percentages, with higher numbers indicating greater impairment and less productivity.	Baseline, Months -2, -3, -4, -5, and -6
Secondary	Patient Sleep Quality as Measured by the Pittsburgh Sleep Quality Index (PSQI)	The PSQI is an instrument used to measure the quality and patterns of sleep; It differentiates "poor" from "good" sleep. It is filled out by the caregiver or the patient and the global sum score ranges from 0 to 21, with higher scores indicating worse sleep quality.	Baseline and Months -2, -4, and -6